Analyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrows
Carnegie analyst Niels Granholm Leth thinks it will be difficult for Cochlear to get its acquisition of Demant’s Oticon More division past the Australian competition authorities, but thinks Demant has other options for divesting.
by albert rønning-andersson, translated by catherine brett
On Thursday morning, the Australia Competition and Consumer Commission (ACCC) expressed concerns about a proposed acquisition of Demant’s surgical division, Oticon More, by Cochlear.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Potential Demant divestment raises competition concerns
For subscribers
